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A B S T R A C T
Intellectual disability is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public
health. Reduced neurogenesis and impaired neuron maturation are considered major determinants of altered
brain function in DS. Since the DS brain starts at a disadvantage, attempts to rescue neurogenesis and neuron
maturation should take place as soon as possible. The brain-derived neurotrophic factor (BDNF) is a neuro-
trophin that plays a key role in brain development by specifically binding to tropomyosin-related kinase receptor
B (TrkB). Systemic BDNF administration is impracticable because BDNF has a poor blood-brain barrier pene-
tration. Recent screening of a chemical library has identified a flavone derivative, 7,8-dihydroxyflavone (7,8-
DHF), a small-molecule that crosses the blood-brain barrier and binds with high affinity and specificity to the
TrkB receptor. The therapeutic potential of TrkB agonists for neurogenesis improvement in DS has never been
examined. The goal of our study was to establish whether it is possible to restore brain development in the
Ts65Dn mouse model of DS by targeting the TrkB receptor with 7,8-DHF. Ts65Dn mice subcutaneously injected
with 7,8-DHF in the neonatal period P3-P15 exhibited a large increase in the number of neural precursor cells in
the dentate gyrus and restoration of granule cell number, density of dendritic spines and levels of the presynaptic
protein synaptophysin. In order to establish the functional outcome of treatment, mice were treated with 7,8-
DHF from P3 to adolescence (P45-50) and were tested with the Morris Water Maze. Treated Ts65Dn mice
exhibited improvement of learning and memory, indicating that the recovery of the hippocampal anatomy
translated into a functional rescue. Our study in a mouse model of DS provides novel evidence that treatment
with 7,8-DHF during the early postnatal period restores the major trisomy-linked neurodevelopmental defects,
suggesting that therapy with 7,8-DHF may represent a possible breakthrough for Down syndrome.
1. Introduction
Down syndrome (DS) is a relatively common genetic condition
(1:750–1000) caused by the triplication of human chromosome 21. One
of the most important consequences of trisomy 21 is a delay in neu-
rological development, which manifests progressively as microcephaly
and intellectual disability (reviewed by (Delabar et al., 2006,
Bartesaghi et al., 2011, Dierssen, 2012, Haydar and Reeves, 2012)).
Neurogenesis reduction and impaired dendritic morphogenesis are the
major neurodevelopmental defects of DS and are thought to underlie
cognitive disability. The molecular mechanisms underlying brain de-
velopment alterations are likely to be manifold, due to the complexity
of gene imbalance in DS, and no therapies currently exist for the rescue
of neurocognitive impairment in DS.
Most of the brain neurons are produced in the prenatal period, with
the notable exception of those involved in the formation of the hippo-
campus, where neurogenesis continues postnatally and throughout life
(Seress et al., 2001; Rice and Barone, 2010; Stiles and Jernigan, 2010;
Spalding et al., 2013). Unlike neurogenesis, neuron maturation and the
establishment of brain wiring largely take place in the perinatal period.
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After the critical periods of neurogenesis and synaptogenesis the brain
can undergo relatively limited plastic changes. Thus, the perinatal
period represents a window of opportunity for therapies aimed at im-
proving the neurodevelopmental alterations of DS. Since the DS brain
starts at a disadvantage, attempts to rescue neurogenesis and neuron
maturation should take place as soon as possible. Previous studies have
shown that perinatal treatment with fluoxetine, a selective serotonin
reuptake inhibitor (SSRI), fully restores brain development and cogni-
tive performance in the Ts65Dn mouse model of DS (Bianchi et al.,
2010b; Guidi et al., 2014). This discovery provides the first evidence
that brain defects due to the trisomic condition are reversible and gives
new hope for therapeutic interventions in individuals with DS. Al-
though fluoxetine is a widely-used antidepressant, that may also be
prescribed in children, its use during pregnancy may cause alterations
in heart development (Reefhuis et al., 2015). Thus, we deem it ex-
tremely important to find molecules that have the same positive impact
as fluoxetine in the trisomic brain but that may pose fewer caveats for
clinical application.
The brain-derived neurotrophic factor (BDNF) is a neurotrophin
that plays a key role in brain plasticity by specifically binding to tro-
pomyosin-related kinase receptor B (TrkB) (Haniu et al., 1997). This
binding causes dimerization and autophosphorylation of the TrkB re-
ceptor, which triggers the activity of several intracellular pathways,
thereby favoring neurogenesis, neuritogenesis and spine growth (see
(Vilar and Mira, 2016)). In the DS brain, BDNF levels are already re-
duced at fetal life stages (Guedj et al., 2009; Toiber et al., 2010) and
reduced BDNF levels have been shown in various brain regions of the
Ts65Dn mouse (Bimonte-Nelson et al., 2003; Bianchi et al., 2010b;
Fukuda et al., 2010; Begenisic et al., 2015). Interestingly, SSRI ad-
ministration increases BDNF levels (Malberg and Blendy, 2005), and a
triangulation between neurogenesis, the serotonergic system, and BDNF
signaling is supported by several findings, suggesting that BDNF-TrkB
signaling may be involved in the pro-neurogenic effects of SSRI anti-
depressants, such as fluoxetine (Gardier et al., 2009; Foltran and Diaz,
2016). Indeed, TrkB ablation in hippocampal neural precursor cells
blocks the increase in proliferation and neurogenesis that occurs in
response to antidepressants (Vilar and Mira, 2016). Consistently with
this evidence, fluoxetine increases BDNF levels in Ts65Dn mice (Bianchi
et al., 2010b; Stagni et al., 2013), suggesting that BDNF may be in-
volved in the beneficial effects of fluoxetine treatment.
In view of the role of the BDNF-TrkB system in neurogenesis and
dendritic morphogenesis, it is conceivable that interventions targeted to
the BDNF-TrkB system may be exploited in order to improve these
defects. Systemic administration of BDNF is impracticable because
BDNF has a poor blood-brain barrier penetration. This obstacle could be
circumvented by using TrkB agonists that can enter the brain. Recent
screening of a chemical library has identified a flavone derivative, 7,8-
dihydroxyflavone (7,8-DHF), as the first small-molecule compound that
binds with high affinity and specificity to the TrkB receptor, activates
its downstream signaling cascade (Liu et al., 2010), and penetrates the
blood-brain barrier (Liu et al., 2013). Administration of 7,8-DHF en-
hances the activation of phosphorylated TrkB and increases spine
density in several brain regions (Zeng et al., 2012), promotes neuro-
genesis in the dentate gyrus (Liu et al., 2010), fosters neurite outgrowth
(Tsai et al., 2013) and exerts therapeutic efficacy in various animal
disease models that are related to deficient BDNF signaling (Liu et al.,
2016).
Various pharmacotherapies have been attempted in DS mouse
models (Bartesaghi et al., 2011; Costa and Scott-McKean, 2013;
Gardiner, 2015). Some of these studies have prompted clinical trials in
children and young adults with DS (De la Torre et al., 2014; de la Torre
et al., 2016) which emphasizes the potential translational impact of
preclinical research. A comparison of the effects of different therapies in
mouse models shows that many of them were effective (Stagni et al.,
2015). It should be noted, however, that some of the used drugs may be
not devoid of side effects, and/or have ephemeral effects, which
diminishes their translational impact. For instance, lithium may impair
the renal function, inhibitors of GABAA receptors may have pro-con-
vulsant effects, melatonin may affect puberty in children. The ther-
apeutic potential of TrkB agonists for neurogenesis improvement in DS
has never been examined. Considering the important role of the BDNF-
TrkB receptor system on neurogenesis, we expect that by acting upon
this system by exploiting the flavonoid 7,8-DHF it may be possible to
positively impact the DS brain. Moreover, considering that flavonoids
are natural substances it seems likely that their administration at ap-
propriate doses may be devoid of side effects. Based on these premises,
we deemed it important to investigate whether treatment with 7,8-DHF
is able to restore trisomy-linked neurogenesis defects. To this purpose,
we exploited the Ts65Dn mouse, a widely-used model of DS. We fo-
cused on the hippocampal formation, one of the most important brain
regions involved in pattern separation/completion and memory for-
mation (Rolls, 2016). The hippocampal dentate gyrus mainly develops
in the early postnatal period in rodents and continues to produce new
neurons throughout life in all species examined including human beings
(Altman and Bayer, 1975; Altman and Bayer, 1990a, 1990b; Spalding
et al., 2013; Workman et al., 2013). We show here that early treatment
with 7,8-DHF restores cellularity and neuron maturation in the hippo-
campal dentate gyrus of the Ts65Dn model of DS and that these effects
are accompanied by restoration of hippocampus-dependent memory.
2. Methods
2.1. Colony
Ts65Dn mice were generated by mating B6EiC3Sn a/A-Ts(17^16)
65Dn females with C57BL/6JEiJ × C3H/HeSnJ (B6EiC3Sn) F1 hybrid
males. This parental generation was provided by Jackson Laboratories
(Bar Harbor, ME, USA). To maintain the original genetic background,
the mice used were of the first generation of this breeding. Animals
were genotyped as previously described (Reinholdt et al., 2011). Be-
cause C3H/HeSnJ mice carry a recessive mutation that leads to retinal
degeneration, animals used for the behavioral study were genotyped by
standard PCR to screen out all mice carrying this gene. The day of birth
was designated postnatal day zero (P0). The animals' health and com-
fort were controlled by the veterinary service. The animals had access
to water and food ad libitum and lived in a room with a 12:12 h light/
dark cycle. Experiments were performed in accordance with the Eur-
opean Communities Council Directive of 24 November 1986 (86/609/
EEC) for the use of experimental animals and were approved by Italian
Ministry of Public Health (813/2016-PR). In this study, all efforts were
made to minimize animal suffering and to keep the number of animals
used to a minimum.
2.2. In vitro experiments
2.2.1. Cultures of SVZ or SGZ neural progenitor cells
Cells were isolated from the subventricular zone (SVZ) of the lateral
ventricle and the subgranular zone (SGZ) of the hippocampal dentate
gyrus (DG) of newborn (P1-P2) euploid and Ts65Dn mice. Briefly,
brains were removed, the SVZ and SGZ regions were isolated and in-
dividually collected in ice-cold PIPES buffer pH 7.4. After centrifuga-
tion, tissue was digested for 10 min at 37 °C using Trypsin/EDTA 0.25%
(Life Technologies) aided by gentle mechanical dissociation. Cell sus-
pension from each individual mouse was plated onto 25 cm2 cell-cul-
ture flask (Thermo Fisher Scientific) and cultured as floating neuro-
spheres in medium containing basic fibroblast growth factor (bFGF,
10 ng/ml; Peprotech) and epidermal growth factor (EGF, 20 ng/ml;
Peprotech) using an established protocol (Meneghini et al., 2014).
Primary (Passage 1, P1) neurospheres were dissociated using Stem-
proAccutase (Life Technologies) after 7 days in vitro (DIV), thereafter
neurospheres were passaged every 5 DIV. For proliferation studies
neurospheres (P3-P12) from the SVZ were dissociated in a single cell
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suspension and plated onto Nunclon™ Delta Surface 96-well plate
(Thermo Fisher Scientific) at a density of 4 × 103 cells per well in
DMEM/F-12 medium supplemented with B27, Glutamax™, heparin
sodium salt (4 μg/ml; ACROS Organics), bFGF (10 ng/ml) and 100 U/
100 μg/ml Penicillin/Streptomycin (Life Technologies) in presence of
7,8-Dihydroxyflavone (7,8-DHF; 0.3–10.0 μM, Sigma Aldrich) or its
vehicle (DMSO 0.06%) for 96 h. Since lithium has been shown to re-
store proliferation of NPCs of Ts65Dn mice in vivo (Bianchi et al.,
2010a; Contestabile et al., 2013) and in vitro (Trazzi et al., 2014), the
effect of exposure to lithium 2 mM was also examined, as positive
control. This dose was chosen based on previous evidence (Trazzi et al.,
2014). Cell proliferation was quantified as relative luminescence units
(RLU) values using CellTiter-Glo viability assay reagent (Promega) on a
Victor3-V plate reader (PerkinElmer). For differentiation experiments
neurospheres from the SVZ and SGZ were dissociated into single cells
and plated onto laminin-coated Lab-Tek 8-well permanox chamber
slides (Thermo Fisher Scientific) at a density of 35 × 103 per well in
differentiation medium (DMEM-F12 supplemented with B27, 2 mM
Glutamax and 100 U/100 mg/ml penicillin/streptomycin). NPCs were
treated in presence of 7,8-DHF (0.3–10.0 μM, Sigma Aldrich) or vehicle
(DMSO 0.02%) for 96 h. Phenotypic characterization of NPC-derived
cells was carried out by immunolocalization for MAP2 (rabbit poly-
clonal, 1:600; Millipore) and Nestin (chicken monoclonal, 1: 1500;
Neuromics). Secondary antibodies were as follows: AlexaFluor555-
conjugated goat anti rabbit (1:1400; MolecularProbes); AlexaFluor488-
conjugated goat anti chicken (1:1400; Molecular Probes). Nuclei were
counterstained with 0.8 ng/ml Hoechst (Thermo Fisher Scientific) di-
luted in PBS. In each experiment, five fields/well (corresponding to
about 150–200 cells/well) were counted with a 60× objective by a
Leica DMIRB inverted fluorescence microscope. Immunoreactive cells
were counted and their percentage over total viable cells was calcu-
lated. The number of MAP2 cells exhibiting neuritic processes was
counted at random locations in five fields/well and their number was
expressed as percentage over total cell number in each sampled loca-
tion. All experiments were run in triplicate.
2.3. In vivo experiments
In the current study, treatment with either 7,8-DHF or vehicle began
on postnatal day 3 (P3). All mice that survived in the P0 to P3 period
entered this study, with no specific selection criteria. A total of 185
mice entered the study (96 males and 89 females). The number of ve-
hicle-treated and 7,8-DHF treated mice was 96 and 89, respectively.
Seven vehicle-treated (7.3%) and five 7,8-DHF-treated (5.6%) mice
died before weaning, in the P6-P22 period. The similarity in the mor-
tality rate across groups suggests that treatment has no adverse effects
on the health of mice.
2.4. Experimental protocol of in vivo experiments
2.4.1. Pilot experiment
In a pilot study we tested the effects of different doses of 7,8-DHF on
the proliferation rate in the SGZ of Ts65Dn mice. Mice received a daily
subcutaneous injection of 7,8-DHF (2.5, 5.0, or 10.0 mg/kg in PBS with
1–2% DMSO) from postnatal day 3 (P3) to P15. On P15, mice received
an intraperitoneal injection (150 μg/g body weight) of BrdU (5-bromo-
2-deoxyuridine; Sigma), a marker of cells in the S-phase of the cell cycle
(Nowakowski et al., 1989) in TrisHCl 50 mM 2 h before being killed and
the number of BrdU positive cells in the SGZ was evaluated. We found
that the optimum dose was 5.0 mg/kg (see Fig. 3A). Therefore, this
study (Experiment 1 and Experiment 2) was carried out using a 5.0 mg/
kg dose.
2.4.2. Experiment 1
Euploid and Ts65Dn mice received a daily subcutaneous injection
(at 9–10 am) of 7,8-DHF (5.0 mg/kg in vehicle: PBS with 1% DMSO) or
vehicle from postnatal day 3 (P3) to postnatal day 15. This timing was
chosen because it corresponds to that previously used to test the effects
of fluoxetine and other pharmacotherapies in the neonate Ts65Dn
mouse (Bianchi et al., 2010b; Giacomini et al., 2015; Stagni et al.,
2016). Mice that received 7,8-DHF will be called “treated mice”
(treated euploid mice: n = 25; treated Ts65Dn mice: n = 15). Mice that
received the vehicle will be called “untreated mice” (untreated euploid
mice: n = 35; untreated Ts65Dn mice: n = 21). On P15, mice received
an intraperitoneal injection (150 μg/g body weight) of BrdU in TrisHCl
50 mM 2 h before being killed (Fig. 2A). The brains were excised and
cut along the midline. The left hemisphere of a group of mice was fixed
by immersion in PFA 4% and frozen, and the left hemisphere of another
group of mice was used for Golgi staining. The right hemispheres of all
mice was kept at −80 °C and used for western blotting.
2.4.3. Experiment 2
Euploid and Ts65Dn mice received a daily subcutaneous injection
(at 9–10 am) of 7,8-DHF (5.0 mg/kg in vehicle) or vehicle from post-
natal day 3 (P3) to postnatal day P45-P50. Mice that did not carry a
recessive mutation that leads to retinal degeneration entered the be-
havioral study (untreated euploid mice: n = 19; untreated Ts65Dn
mice: n = 14; treated euploid mice: n = 17; treated Ts65Dn mice:
n = 16). These mice will be called here P45 mice. Mice were beha-
viorally tested in the 6 days that preceded the day of sacrifice (Fig. 2B).
The body weight of mice of all groups was recorded prior to sacrifice
and the brain weight was recorded immediately after brain removal.
The number of animals used for each experimental procedure is spe-
cified in the figure legends and in Supplementary Table 1.
2.5. Histological procedures
The frozen brains were cut with a freezing microtome into 30-μm-
thick coronal sections that were serially collected in anti-freezing so-
lution (30% glycerol; 30% ethylene glycol; 10% PBS10X; sodium azide
0.02%; MilliQ to volume).
2.6. Immunohistochemistry
Immunohistochemistry (IHC) was carried out as previously de-
scribed (Contestabile et al., 2007; Bianchi et al., 2010b; Guidi et al.,
2013; Giacomini et al., 2015).
2.6.1. BrdU immunohistochemistry
One out of six free-floating sections (n = 15–18 sections) from the
hippocampal formation of P15 mice was incubated with rat anti-BrdU
antibody. Detection was performed with a Cy3-conjugated anti rat-
secondary antibody as indicated in Table 1.
2.7. Golgi staining
Brains of P15 mice were Golgi stained using the FD Rapid Golgi
Stain ™ Kit (FD NeuroTechnologies, Inc.). Brains were immersed in the
impregnation solution containing mercuric chloride, potassium di-
chromate and potassium chromate and stored at room temperature in
darkness for 3 weeks. Hemispheres were cut with a microtome in 90-
μm-thick coronal sections that were mounted on gelatin-coated slides
and were air dried at room temperature in the dark for one day. After
drying, sections were rinsed with distilled water and subsequently
stained in a developing solution (FD Rapid Golgi Stain Kit).
2.8. Measurements
2.8.1. Image acquisition
Immunofluorescence images were taken with a Nikon Eclipse TE
2000-S inverted microscope (Nikon Corp., Kawasaki, Japan), equipped
with a Nikon digital camera DS 2MBWc. Measurements were carried
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out using the software Image Pro Plus (Media Cybernetics, Silver
Spring, MD 20910, USA). Bright field images were taken on a light
microscope (Leitz) equipped with a motorized stage and focus control
system and a Coolsnap-Pro color digital camera (Media Cybernetics,
Silver Spring, MD, USA).
2.8.2. BrdU-positive cells
BrdU-positive cells in the DG of P15 mice were detected using a
fluorescence microscope (Eclipse; objective: ×40, 0.75 NA; final
magnification: ×400). Quantification of BrdU-labeled nuclei was con-
ducted in every 6th section using a modified unbiased stereology pro-
tocol that has previously been reported as successfully quantifying BrdU
labeling (Malberg et al., 2000; Kempermann and Gage, 2002; Tozuka
et al., 2005). All BrdU labeled cells located in the granule cell and
subgranular layers were counted in their entire z axis (1 μm steps) in
each section. To avoid oversampling errors, nuclei intersecting the
uppermost focal plane were excluded. The total number of BrdU labeled
cells per animal was determined and multiplied by six to obtain the
total estimated number of cells per DG.
2.8.3. Stereology of the DG
Unbiased stereology was performed on Hoechst-stained sections
from P15 mice. The optical dissector method was used to obtain den-
sity, and Cavalieri principle was used to estimate volume (West and
Gundersen, 1990). To include 15–20 sections, one every 6th section was
selected, beginning at a random position within the first 6 sections. In
order to obtain granule cell numerical density, counting frames (dis-
ectors) with a side length of 30 μm and a height of 10 μm spaced in a
100 μm square grid were systematically used. Granule cell nuclei were
counted with a ×64 oil objective (1.4 NA). Granule cell nuclei inter-
secting the uppermost focal plane and intersecting the exclusion lines of
the count frame were not counted. The neuron density (NV) is given by
=N (ΣQ Σdis) VdisV
where Q is the number of particles counted in the disectors, dis is
the number of disectors and Vdis is the volume of the disector. For
calculation of Vdis the disector height was corrected for section
shrinkage in the z-plane (Dorph Petersen et al., 2001) according to the
formula: h = counting thickness × (original thickness / measured
thickness). The section thickness was measured during neuron counting
at different random locations. In the analyzed sections, the mean sec-
tion thickness was 16 μm (range: 12–18 μm). For volume (Vref) esti-
mation with the Cavalieri principle, in each sampled section, the area of
the granule cell layer was measured by tracing its contours. The volume
of the granule cell layer (Vref) was estimated (West and Gundersen,
1990) by multiplying the sum of the cross sectional areas by the spacing
T between sampled sections (180 μm). The total number (N) of granule
cells was estimated as the product of Vref and the numerical density
(NV).
═ ×N N VV ref
2.9. Spine density
In Golgi-stained sections from the DG of P15 mice, spines of granule
cells were counted using a 100× oil immersion objective lens (1.4 NA).
Spine density values were obtained from dendritic segments in the
inner and outer half of the molecular layer. For each neuron, 2–3 seg-
ments were analyzed in the outer and inner half of the molecular layer,
respectively. For each animal, spines were counted in at least 8 neurons.
The length of each sampled dendritic segment was determined by tra-
cing its profile and the number of spines was counted manually. The
linear spine density was calculated by dividing the total number of
spines by the length of the dendritic segment. Spine density was ex-
pressed as number of spines per 100 μm dendrite.
2.10. Western blotting
In homogenates of the hippocampal formation of P15 mice, total
proteins were obtained as previously described (Trazzi et al., 2011) and
the levels of the following proteins were evaluated: BDNF, TrkB full
length (TrkB-FL), phosphorylated TrkB (p-TrkB), the truncated form 1
of the TrkB receptor (TrkB-T1), phosphorylated ERK1 (p-ERK1), phos-
phorylated ERK2 (p-ERK2), ERK1, ERK2, synaptophysin (SYN), GAPDH
Table 1
Antibodies used for immunohistochemistry and Western blotting.
Antigen Application Antibody dilution-manufactures
α-Tubulin WB Primary: mouse monoclonal 1:1000 (Clone B-5-1-2) (Sigma-Aldrich, T5168)
Secondary: HRP-conjugated anti-mouse 1:20000 (Jackson Immunoresearch, 115-
035-003)
Brain-derived neurotrophic factor (BDNF) WB Primary: rabbit polyclonal 1:500 (N-20) (Santa Cruz Biotechnology, cs-546)
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson Immunoresearch, 111-035-
003)
5-Bromo-2-deoxyuridine (BrdU) IHC Primary: rat monoclonal 1:200 (BioRad, OBT0030)
Secondary: Cy3-conjugated anti-rat IgG 1:200 (Jackson Immunoresearch, 112-165-
143)
Extracellular signal-regulated kinase (ERK1/2) WB Primary: mouse monoclonal 1:1000 (3A7) (Cell Signaling Technology, 9107)
Secondary: HRP-conjugated anti-mouse 1:10000 (Jackson Immunoresearch, 115-
035-003)
phosphorylated ERK (p-ERK1/2) WB Primary: rabbit polyclonal 1:1000 (Cell Signaling Technology, 9101)
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson Immunoresearch, 111-035-
003)
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) WB Primary: rabbit polyclonal 1:5000 (Sigma-Aldrich, G9545)
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson Immunoresearch, 111-035-
003)
Synaptophysin (SYN) WB Primary: rabbit polyclonal 1:1000 (Abcam, ab 14692)
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson Immunoresearch, 111-035-
003)
Tropomyosin receptor kinase (Trk) B Full Length (FL) and TrkB truncated
(T1)
WB Primary: rabbit monoclonal 1:1000 (Cell Signaling Technology, 80E3)
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson Immunoresearch, 111-035-
003)
Phosphorylated TrkB-FL (p-TrkB-FL) WB Primary: rabbit polyclonal 1:1000 (Millipore, ABN1381)
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson Immunoresearch, 111-035-
003)
Abbreviations: IHC, immunohistochemistry; WB, Western blotting.
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and α-Tubulin using the antibodies reported in Table 1. Densitometric
analysis of digitized images with ChemiDoc XRS+ was performed with
Image Lab software (Bio-Rad Laboratories, Hercules, CA, USA) and
intensity for each band was normalized to the intensity of the corre-
sponding GAPDH or α-Tubulin band.
2.11. Behavioral testing
2.11.1. Morris Water Maze (MWM)
Mice were trained in the MWM task to locate a hidden escape
platform in a circular pool, using a previously used protocol (Stagni
et al., 2016), that was altogether based on a published protocol
(Vorhees and Williams, 2006). The apparatus consisted of a large cir-
cular water tank (1.00 m diameter, 50 cm height) with a transparent
round escape platform (10 cm2). The pool was virtually divided into
four equal quadrants identified as northeast, northwest, southeast, and
southwest. The tank was filled with tap water at a temperature of
22 ± 1.0 °C. Mice are more prone to undergo hypothermia than rats
and in the MWM hypothermia may cause a reduction in swimming
speed (Iivonen et al., 2003). Evaluation of the swimming speed showed
no speed differences across consecutive trials, suggesting that at this
temperature mice did not undergo hypothermia (Supplementary
Fig. 1). This is consistent with evidence that a temperature of 22 °C is
“high enough” to reduce stress and potential hypothermia and “low
enough” to maintain the animals' motivation to escape the pool (Costa
et al., 2010). The tank was filled with water up to 0.5 cm above the top
of the platform and the water was made opaque with milk. The plat-
form was placed in the tank in a fixed position (in the middle of the
south-west quadrant). The pool was placed in a large room with various
intra- (squares, triangles, circles and stars) and extra-maze visual cues.
Each mouse was tested in one session of 4 trial on the first day and in
two sessions of 4 trials in the following 4 days with an inter-session
interval of 45 min. A video camera was placed above the center of the
pool and connected to a videotracking system (Ethovision 3.1; Noldus
Information Technology B.V., Wageningen, Netherlands). Mice were
released facing the wall of the pool from one of the following starting
points: North, East, South, or West and allowed to search for up to 60 s
for the platform. If a mouse did not find the platform, it was gently
guided to it and allowed to remain there for 15 s. During the inter-trail
time (10 s) mice were placed in an empty cage. For the learning phase,
we evaluated the latency to find the hidden platform, time in periphery,
percentage of time in periphery, path length, proximity to the platform,
and swimming speed. Retention was assessed with one trial (probe
trial), on the sixth day, 24 h after the last acquisition trial, using the
same starting point for all mice. Mice were allowed to search for up to
60 s for the platform. For the probe trial, the latency of the first en-
trance in the former platform zone, the frequency of entrances in the
former quadrant, the proximity to the former platform position (Gal-
lagher's test), the percentage of time spent at the periphery (thigmo-
taxis), the swimming speed and the percentage of time spent in each
quadrant were employed as measures of retention of acquired spatial
preference. All experimental sessions were carried out between 9.00 am
and 5.00 pm. The following number of mice were tested. Untreated
euploid mice: n = 19; untreated Ts65Dn mice: n = 14; 7,8-DHF-treated
euploid mice: n = 17; 7,8-DHF-treated Ts65Dn mice: n = 16. Three
untreated euploid mice (yielding n = 16), one 7,8-DHF-treated euploid
mouse (yielding n = 16) and one 7,8-DHF-treated Ts65Dn mouse
(yielding n = 15) were excluded from MWM analysis due to thigmo-
taxis for a whole recording session.
2.12. Statistical analysis
Results are presented as mean ± standard error of the mean (SE).
Data were analyzed with the IBM SPSS 22.0 software. Statistical ana-
lysis was carried out using either a one-way ANOVA or a two-way
ANOVA with genotype (euploid, Ts65Dn) and treatment (vehicle, 7,8-
DHF), as factors. Post hoc multiple comparisons were carried out using
the Fisher least significant difference (LSD) test. For the learning phase
of the MWM test, statistical analysis was performed using a three-way
mixed ANOVA, with genotype and treatment as grouping factors and
days as a repeated measure. For the probe test of MWM, we used a two-
way ANOVA with genotype and treatment as factors followed by the
Fisher LSD post hoc test for the latency of the first entrance in the former
platform zone, the frequency of entrances in the former quadrant, the
proximity to the former platform position, the percentage of time spent
at the periphery, and the swimming speed. For the percentage of time
spent in quadrants, the percentage of time spent in the NW, NE and SE
quadrants was compared to the percentage of time spent in the former
platform quadrant (SW), respectively, with a paired-samples t-test.
Based on the “Box plot” tool available in SPSS Descriptive Statistics we
excluded from each analysis the extremes, i.e. values that were larger
than 3 times the IQ range [x≥ Q3 + 3 ∗ (IQ); x≤ Q1–3 ∗ (IQ)]. The
number of mice included and excluded in individual analyses is re-
ported in Supplementary Table 1. Figure legends report the number of
mice used for statistical analysis. Supplementary Tables 2–7 report the
p values of the post-hoc LSD or paired-samples t-test for each analysis. A
probability level of p≤ 0.05 was considered to be statistically sig-
nificant.
3. Results
3.1. Effect of treatment with 7,8-DHF on proliferation, differentiation and
maturation of trisomic NPCs
Confirming previous evidence (Trazzi et al., 2011; Trazzi et al.,
2013), neural progenitor cells (NPCs) from the subventricular zone
(SVZ) of neonate Ts65Dn mice exhibit impairment of proliferation rate
(Fig. 1A). Cultures of trisomic NPCs were exposed to standard medium
(vehicle) or standard medium plus different concentrations of 7,8-DHF,
in order to establish whether treatment increases their proliferation
rate. A one-way ANOVA showed a significant effect of treatment [F
(5,12) = 81.364, p≤ 0.001]. A post hoc LSD test showed that none of
the tested concentrations was able to increase the proliferation rate of
trisomic NPCs and that the highest concentration (10.0 μM) even re-
duced proliferation (Fig. 1B). In contrast, cells were highly responsive
to the pro-proliferative action of 2 mM lithium (Fig. 1B). In addition to
proliferation impairment, trisomic NPCs exhibit impairment in the ac-
quisition of a neuronal phenotype and maturation, i.e. development of
neuritic processes (Trazzi et al., 2011; Trazzi et al., 2013). In order to
establish whether treatment favors neurogenesis, in cultures of NPCs
under differentiating conditions we evaluated the percentage of cells
positive to MAP2, a marker of cells with a neuronal phenotype, and of
cells positive to Nestin, a marker of neural stem cells. A one-way
ANOVA on the percentage of cells that were MAP2-positive and Nestin-
negative (MAP2+/Nestin−) showed a significant effect of treatment
[F(5,12) = 9.354, p≤ 0.001]. A post-hoc LSD test showed that all drug
concentrations caused a large increase in the percentage of MAP2+/
Nestin− cells in comparison with cultures in the standard medium
(Fig. 1C). Consistently with the lack of effect of treatment on the pro-
liferation rate of NPCs (Fig. 1B) we found no change in the percentage
of cells that were Nestin-positive and MAP2-negative (Nestin
+/MAP2−; Fig. 1D). This evidence suggests that treatment does not
affect the proliferation rate of neural stem cells but enhances the dif-
ferentiation of their progeny into neurons. In order to establish the
effect of 7,8-DHF on neuron maturation we evaluated the percentage of
cells exhibiting neuritic processes in differentiating cultures of trisomic
NPCs from the SVZ and from the subgranular zone (SGZ) of the dentate
gyrus (DG), exposed to different concentrations of 7,8-DHF. A one-way
ANOVA on the percentage of NPCs from the SGZ that exhibited neuritic
processes showed a significant effect of treatment [F(5,12) = 4.336,
p = 0.017]. A post-hoc LSD test showed that concentrations higher than
1.0 μM increased the percentage of differentiating cells in comparison
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with cultures in the standard medium (Fig. 1E,F). A one-way ANOVA on
the percentage of NPCs from the SVZ that exhibited neuritic processes
showed a significant effect of treatment [F(5,12) = 12.364,
p≤ 0.001]. A post-hoc LSD test showed that doses higher than 0.3 μM
increased the percentage of differentiating cells in comparison with
cultures in the standard medium (Fig. 1G,H). Observation of Fig. 1F,H
shows that effect of treatment on neuron maturation increased in a
concentration-dependent manner. Evaluation of the number of apop-
totic cells showed no effect of treatment (data not shown). Taken to-
gether these data show that 7,8-DHF does not increase the proliferation
rate but fosters the process of neurogenesis and neuron maturation in
cultures of NPCs.
3.2. Effect of treatment with 7,8-DHF in vivo: general results
The Ts65Dn strain is characterized by a high mortality rate during
gestation (Roper et al., 2006). For this reason, the number of Ts65Dn
pups in a litter results approximately 30% instead of the theoretical
value of 50%. Moreover, Ts65Dn mice exhibit a high mortality rate
before weaning (Roper et al., 2006). This means that numerous litters
are needed in order to obtain a sufficiently large number of Ts65Dn
mice. In view of the fragility of this strain, we deemed it important to
establish whether treatment with 7,8-DHF has adverse effects on the
viability and growth of Ts65Dn mice. In the current study, treatment
with either 7,8-DHF or vehicle began on postnatal day 3 (P3). All mice
that survived in the P0 to P3 period entered this study, with no specific
selection criteria. We found that 7.3% of the vehicle-treated mice and
5.6% of the 7,8-DHF-treated mice died before weaning, in the P6-P22
period. The similarity in the mortality rate across groups suggests that
treatment has no adverse effects on the health of mice.
We evaluated the body and brain weight of P15 and P45 mice in
order to establish the effect treatment on gross growth parameters. A
two-way ANOVA on the body weight of P15 mice showed no genoty-
pe × treatment interaction [F(1,92) = 0.63, p = 0.431], no main ef-
fect of treatment but a main effect of genotype [F(1,92) = 14.78,
p≤ 0.001]. Post hoc LSD test confirmed well established evidence that
Ts65Dn mice have a reduced body weight in comparison with euploid
mice and showed that treatment did not further reduce the body weight
of Ts65Dn mice (Fig. 2C). A two-way ANOVA on the brain weight of
P15 mice showed no genotype × treatment interaction [F(1,92)
= 1.09, p = 0.300], a main effect of genotype [F(1,92) = 7.73,
p = 0.007] and a main effect of treatment [F(1,92) = 6.18,
Fig. 1. Effect of 7,8-DHF on proliferation, differentiation
and maturation of trisomic NPCs. A: Number of pro-
liferating cells in cultures of neural progenitor cells (NPCs)
from the SVZ of euploid and Ts65Dn mice. Data are ex-
pressed as fold change in comparison with euploid NPCs.
**p≤ 0.01, two-tailed t-test. B: Effect of different con-
centrations of 7,8-DHF or LiCl 2.0 mM on the proliferation
rate of NPCs from the SVZ of Ts65Dn mice. Data are ex-
pressed as fold change in comparison with NPCs exposed to
vehicle alone (DMSO 0.06%). C,D: Percentage of MAP2+/
Nestin− cells (C) and of Nestin+/MAP2− cells (D) in
cultures of NPCs from the SVZ of Ts65Dn mice grown under
differentiating conditions and exposed to different con-
centrations of 7,8-DHF for 96 h. E–H: Percentage of cells
exhibiting neuritic processes (red) in cultures of NPCs from
the SGZ (F) and SVZ (H) of Ts65Dn mice grown under
differentiating conditions and exposed to different doses of
7,8-DHF for 96 h. Images in (E,G) show cells from the SGZ
(E) and SVZ (G) of Ts65Dn mice that were exposed to either
vehicle (DMSO 0.02%) or 7,8-DHF 5.0 μM. Scale
bar = 50 μm. Data in A–H were obtained in pooled cultures
from euploid (n = 4) and Ts65Dn (n = 3) mice. The as-
terisks in (A, B, C, F, H) indicate a difference in comparison
with untreated cultures exposed to DMSO alone [(*)
p≤ 0.06; *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001 (Fisher
LSD test after ANOVA)]. The symbol # in (B) indicates a
difference between cultures exposed to LiCl and cultures
exposed to vehicle alone (### p≤ 0.001, two-tailed t-
test). Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu,
euploid; LiCl, Lithium chloride; MAP2, microtubule asso-
ciated protein 2; SGZ, subgranular zone; SVZ, sub-
ventricular zone. (For interpretation of the references to
color in this figure legend, the reader is referred to the web
version of this article.)
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p = 0.015]. Post hoc LSD test showed that Ts65Dn mice had a reduced
brain weight in comparison with euploid mice and that treatment did
not cause a further brain weight reduction (Fig. 2D). On the contrary,
treated euploid mice underwent a slight but significant brain weight
reduction in comparison with their untreated counterparts (Fig. 2D).
A two-way ANOVA on the body weight of P45 mice showed no
genotype × treatment interaction [F(1,62) = 1.57, p = 0.215], no
main effect of treatment but a main effect of genotype [F(1,62) = 4.98,
p = 0.029]. Post hoc LSD test showed that Ts65Dn mice retained a re-
duced body weight in comparison with euploid mice and that treatment
did not further reduce their body weight (Fig. 2E). In contrast, treated
euploid mice underwent a body weight reduction in comparison with
their untreated counterparts (Fig. 2E). A two-way ANOVA on the brain
weight of P45 mice showed no genotype × treatment interaction [F
(1,62) = 2.06, p = 0.156], no main effect of either genotype or treat-
ment. Post hoc LSD test showed that untreated Ts65Dn mice had a re-
duced brain weight in comparison with untreated euploid mice and that
this difference disappeared in Ts65Dn mice treated with 7,8-DHF
(Fig. 2F). Taken together these findings show that treatment with 7,8-
DHF has no adverse effects on viability and body weight of Ts65Dn
mice and that it has a positive impact on their brain weight.
3.3. Effect of neonatal treatment with 7,8-DHF on neural precursor
proliferation in the hippocampal dentate gyrus of Ts65Dn mice
Recent work has examined the effect of 7,8-DHF in models of
Alzheimer disease. A dose of 5.0 mg/kg has been shown to have no
toxic effects and to restore cognitive performance (Liu et al., 2010). In
addition, this dose increases the proliferation rate of neural precursor
cells of the DG (Liu et al., 2010). In order to establish whether this is the
optimal dose for proliferation enhancement in Ts65Dn mice, we treated
pups with vehicle, 2.5 mg/kg, 5.0 mg/kg or 10.0 mg/kg of 7,8-DHF in
the period P3-P15. At the end of treatment, mice received one injection
of BrdU and were killed after 2 h in order to examine the effect of
treatment on proliferation rate. A one-way ANOVA on the number of
BrdU-positive cells in the DG of Ts65Dn pups showed a significant effect
of treatment [F(3,20) = 4.15, p = 0.019]. Post hoc LSD test showed
that the lowest dose had no effect in comparison with vehicle-treated
mice and that both the 5.0 mg/kg and the 10.0 mg/kg doses increased
the number of BrdU-positive cells in Ts65Dn mice. In absolute terms,
the 5.0 mg/kg dose had a higher pro-proliferative effect than the
10.0 mg/kg dose (Fig. 3A).
Based on the results reported above, all following experiments in
vivo were carried out using a 5.0 mg/kg dose. In order to establish the
effects of 7,8-DHF on proliferation rate of NPCs of the DG, Ts65Dn mice
and their euploid littermates were daily injected with 5.0 mg/kg of 7,8-
DHF in the period P3-P15. At the end of treatment, mice were injected
with BrdU and the number of BrdU-positive cells in the SGZ of the DG
was evaluated. A two-way ANOVA on the total number of BrdU-positive
cells showed a genotype × treatment interaction [F(1,19) = 8.53,
p = 0.009], a main effect of genotype [F(1,19) = 21.25, p≤ 0.001],
but no effect of treatment. A post hoc Fisher LSD test showed that, in
Fig. 2. Experimental protocol and general results of the in
vivo experiments. A: Euploid and Ts65Dn pups received one
daily injection of either vehicle or 7,8-DHF from postnatal
day 3 (P3) to P15. At P15, mice received one injection of
BrdU, and were killed after 2 h in order to evaluate the
number of cells in the S-phase of the cell cycle. B: Euploid
and Ts65Dn mice received one daily injection of either
vehicle or 7,8-DHF from postnatal day P3 to P45-50. These
mice were tested with the Morris Water Maze test 6 days
before being killed. C,D: Body (C) and brain (D) weight
(mean ± SE) in grams of P15 euploid (n = 35) and
Ts65Dn (n = 21) mice that received vehicle and euploid
(n = 25) and Ts65Dn (n = 15) mice that received 7,8-DHF
(5.0 mg/kg) in the period P3-P15. E,F: Body (E) and brain
(F) weight (mean ± SE) in grams of P45 euploid (n = 19)
and Ts65Dn (n = 14) mice that received vehicle and eu-
ploid (n = 17) and Ts65Dn (n = 16) mice that received
7,8-DHF (5.0 mg/kg) in the period P3-P45. *p≤ 0.05;
**p≤ 0.01; ***p≤ 0.001 (Fisher LSD test after two-way
ANOVA). Black asterisks in the gray bar indicate a differ-
ence between untreated Ts65Dn mice and treated euploid
mice. White asterisks in the black bar indicate a difference
between treated Ts65Dn mice and treated euploid mice.
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; BrdU, 5-
bromo-2-deoxyuridine; Eu, euploid; MWM, Morris Water
Maze; P, postnatal.
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agreement with previous evidence (Bianchi et al., 2010b), untreated
Ts65Dn mice had notably fewer proliferating cells in comparison with
untreated euploid mice (total number per DG in Ts65Dn mice:
n = 7166 ± 337, in euploid mice: n = 10,281 ± 111). The number
of proliferating cells in treated Ts65Dn mice underwent an increase
(n = 8963 ± 449) and became statistically greater than that of their
untreated counterparts, although it remained slightly lower in com-
parison with untreated euploid mice (Fig. 3B,C). Treatment had no
effect on the number of NPCs in euploid mice (Fig. 3B,C). These results
show that treatment in vivo, unlike in vitro, greatly enhances cell pro-
liferation in trisomic mice, although the number of proliferating cells
does not reach the same value as euploid mice.
3.4. Effect of 7,8-DHF on the number of granule neurons in the dentate
gyrus of Ts65Dn mice
In view of the treatment-induced increase in the proliferation po-
tency of neural precursor cells of the DG, we expected this effect to lead
Fig. 3. Effects of neonatal treatment with 7,8-DHF on the size of the population of cells in the S-phase of the cell cycle in the dentate gyrus (DG) of P15 Ts65Dn and euploid mice. A: In
pilot experiments Ts65Dn mice received a daily injection of vehicle (n = 8) or 7,8-DHF (2.5 mg/kg, n = 4; 5.0 mg/kg, n = 5; 10.0 mg/kg, n = 7) in the period P3-P15. At P15, they were
injected with BrdU and killed after 2 h. The histograms show the number of BrdU-positive cells in the DG of Ts65Dn mice treated with either vehicle or the indicated doses of 7,8-DHF.
The number of BrdU-positive cells in euploid mice reported in (C) that received the vehicle is shown for comparison. B: Representative images of sections immunostained for BrdU from
the DG of untreated euploid and Ts65Dn mice and euploid and Ts65Dn mice that were daily treated with 5.0 mg/kg of 7,8-DHF in the period P3-P15. Calibration bar = 200 μm. The
insets show zoomed images of the boxed area with examples of individual BrdU-positive cells. Calibration bar = 20 μm. C: Total number of BrdU-positive cells in the DG of untreated
euploid (n = 7) and Ts65Dn (n = 8) mice and euploid (n = 3) and Ts65Dn (n = 5) mice treated with 5.0 mg/kg of 7,8-DHF. Values (mean ± SE) in (A) and (C) refer to one hemisphere.
*p≤ 0.05; **p≤ 0.01; ***p≤ 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid
mice. Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid.
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to improvement/restoration of the defective cellularity that char-
acterizes the DG of trisomic mice (Bianchi et al., 2010b). To clarify this
issue, we stereologically evaluated the total number of granule cells in
treated and untreated mice. A two-way ANOVA on total number of
granule cells showed a genotype × treatment interaction [F(1,13)
= 6.71, p = 0.022], but no main effect of either genotype or treatment.
A post hoc Fisher LSD test showed that untreated Ts65Dn mice had
fewer granule neurons in comparison with euploid mice and that
treatment caused a large increase in their number. Consequently, in
treated Ts65Dn mice the number of granule cells became similar to that
of untreated euploid mice (Fig. 4A,B). Unlike in Ts65Dn mice, in eu-
ploid mice treatment had no effect on total number of granule cells
Fig. 4. Effects of neonatal treatment with 7,8-DHF on granule
cell number in the dentate gyrus (DG) of P15 Ts65Dn and
euploid mice. A: Representative images of Hoechst-stained
sections showing the granule cell layer of an animal from each
experimental group. Calibration bar = 100 μm. B: Total
number of granule cells of untreated euploid (n = 4) and
Ts65Dn (n = 4) mice and euploid (n = 4) and Ts65Dn mice
(n = 5) treated with 5.0 mg/kg 7,8-DHF. Values
(mean ± SE) refer to one DG. *p≤ 0.05 (Fisher LSD test
after two-way ANOVA). Abbreviations: 7,8-DHF, 7,8-dihy-
droxyflavone; Eu, euploid; GR, granule cell layer; SGZ, sub-
granular zone; Veh, vehicle.
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(Fig. 4A,B). These results show that neonatal treatment with 7,8-DHF
restores the typical hypocellularity that characterizes the DG of trisomic
mice.
3.5. Effect of 7,8-DHF on dendritic spine density in the dentate gyrus of
Ts65Dn mice
Spine density reduction is a typical feature of the trisomic brain
(Benavides-Piccione et al., 2004; Guidi et al., 2013) that, in conjunction
with hypocellularity, is thought to be a critical determinant of in-
tellectual disability. In order to establish whether 7,8-DHF improves
this defect, in Golgi stained brains we evaluated spine density in the
dendritic arbor of granule neurons. Since no differences between spine
density on proximal and distal dendritic branches were found data were
pooled together. A two-way ANOVA on spine density showed a geno-
type × treatment interaction [F(1,12) = 13.23, p = 0.003], a main
effect of genotype [F(1,12) = 19.93, p = 0.001] and a main effect of
treatment [F(1,12) = 42.30, p≤ 0.001]. A post hoc Fisher LSD test
showed that untreated Ts65Dn had a considerably reduced spine den-
sity in comparison with untreated euploid mice (Fig. 5C). After treat-
ment with 7,8-DHF the number of spines of Ts65Dn mice underwent a
notable increment and became similar to that of euploid mice (Fig. 5C),
indicating that treatment fully rescues spine development. In euploid
mice treatment had no effect on spine density (Fig. 5C).
3.6. Effect of 7,8-DHF on synaptophysin levels in the hippocampal
formation of Ts65Dn mice
Circuit formation is critically shaped in the early postnatal period
throughout the brain. The trisomic brain is characterized by altered
synaptic connectivity that, in conjunction with hypocellularity and
dendritic pathology, largely contributes to impairment of signal pro-
cessing (Bartesaghi et al., 2011). Synaptophysin (SYN) is a protein of
the synaptic vesicles and is, therefore, a marker of synaptic terminals.
To establish whether treatment with 7,8-DHF had an effect on synapse
development, we examined the expression levels of SYN in the hippo-
campus of P15 mice.
A two-way ANOVA on the levels of SYN showed no interaction
between genotype and treatment [F(1,27) = 0.82, p = 0.372], no main
effect of genotype, but a main effect of treatment [F(1,27) = 6.62,
p = 0.016]. Confirming previous evidence (Stagni et al., 2013), a post
hoc Fisher LSD test showed that untreated Ts65Dn mice had reduced
SYN levels in comparison with untreated euploid mice, although the
difference was marginally significant, and that treatment with 7,8-DHF
Fig. 5. Effects of neonatal treatment with 7,8-
DHF on dendritic spine density and synapto-
physin levels in the dentate gyrus of P15 Ts65Dn
and euploid mice. A: The photomicrograph shows
a Golgi-stained granule cell. Dendritic spines
were counted in the inner and outer half of the
dendritic arbor of the granule cells. Calibration
bar = 10 μm. B: Photomicrograph of Golgi-
stained granule cell dendrites showing spines on
distal dendritic branches in an animal from each
experimental groups. Calibration bar = 5 μm. C:
Spine density on the dendritic arbor of the
granule cells of untreated euploid (n = 4) and
Ts65Dn mice (n = 4) and euploid (n = 4) and
Ts65Dn (n = 4) mice treated with 7,8-DHF. D:
Western blot analysis of the expression levels of
synaptophysin (SYN) in hippocampal homo-
genates of untreated euploid (n = 10) and
Ts65Dn (n = 10) mice and treated euploid
(n = 5) and Ts65Dn (n = 6) mice. SYN levels
were normalized to GAPDH and expressed as fold
difference in comparison with untreated euploid
mice. Representative western blots are shown on
the right. Values in (C,D) are mean ± SE. (*)
p≤ 0.06; *p≤ 0.05; ***p≤ 0.001 (Fisher LSD
test after two-way ANOVA). Black asterisks in the
gray bar indicate a difference between untreated
Ts65Dn mice and treated euploid mice.
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone;
Eu, euploid; Veh, Vehicle.
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increased SYN levels that became similar to those of untreated euploid
mice (Fig. 5D). An increase in SYN levels also took place in treated
euploid mice in comparison with their untreated counterparts (Fig. 5D).
These findings suggest that treatment with 7,8-DHF restores develop-
ment of hippocampal synapses in Ts65Dn mice and enhances synaptic
development in euploid mice.
3.7. Effect of 7,8-DHF on the BDNF-TrkB receptor system in the
hippocampal formation of Ts65Dn mice
BDNF signaling is elicited when it binds to TrkB, resulting in the
receptor dimerization and autophosphorylation. TrkB, the high affinity
receptor of BDNF, and BDNF are essential for normal brain function
(Bibel et al., 1999). The TrkB full-length receptor (TrkB-FL) possesses
an intracellular tyrosine kinase domain and is considered to mediate the
crucial effects of BDNF. By contrast, the truncated form 1 of the TrkB
receptor (TrkB-T1) lacks tyrosine kinase activity. It mediates inositol-
1,4,5-trisphosphate-dependent calcium release (Rose et al., 2003). We
examined the protein levels of BDNF and TrkB receptors in the hippo-
campus of P15 euploid and Ts65Dn mice in order to establish the effect
of genotype and treatment on the BDNF-TrkB system.
A two-way ANOVA on the BDNF levels showed no genotype × -
treatment interaction [F(1,48) = 0.86, p = 0.359], a main effect of
treatment [F(1,48) = 8.76, p = 0.005], but no effect of genotype. A
post hoc Fisher LSD test showed that Ts65Dn mice had similar BDNF
protein levels as euploid mice (Fig. 6B). Treatment with 7,8-DHF caused
a reduction in BDNF levels both in euploid and Ts65Dn mice although
the difference was statistically significant for the latter only (Fig. 6B). A
two-way ANOVA on the levels of TrkB-FL receptor showed no genoty-
pe × treatment interaction [F(1,45) = 2.17, p = 0.148], a main effect
of genotype [F(1,45) = 5.71, p = 0.021] and no effect of treatment. A
post hoc Fisher LSD test showed no difference between untreated eu-
ploid and Ts65Dn mice in the levels of TrkB-FL (Fig. 6A,C). In Ts65Dn,
but not in euploid mice, treatment with 7,8-DHF caused a reduction in
the levels of TrkB-FL (Fig. 6A,C). A two-way ANOVA on the levels of the
phosphorylated form of TrkB receptor (p-TrkB-FL) showed no genoty-
pe × treatment interaction [F(1,39) = 0.03, p = 0.865], a main effect
of treatment [F(1,39) = 10.88, p = 0.002] but no main effect of gen-
otype. A post hoc Fisher LSD test showed that in untreated Ts65Dn mice
the levels of p-TrkB-FL were similar to those of euploid mice. In both
genotypes, treatment with 7,8-DHF caused an increase in the levels of
p-TrkB-FL (Fig. 6A,D). A two-way ANOVA on the levels of the TrkB-T1
receptor showed a genotype × treatment interaction [F(1,47) = 6.04,
p = 0.018], but no main effect of either treatment or genotype. A post
hoc Fisher LSD test showed that untreated Ts65Dn mice has similar
levels of TrkB-T1 as untreated euploid mice. Treated Ts65Dn mice
underwent a reduction in the levels of TrkB-T1 in comparison with their
untreated counterparts and untreated euploid mice (Fig. 6A,E).
The activation of the TrkB-FL receptor allows its interaction with
molecules that further interact and modify downstream targets, in-
cluding the RAS/ERK signaling pathway. Since RAS/ERK signaling is
involved in cell proliferation and differentiation, we examined the ef-
fects of treatment on the activation of ERK1/2 in hippocampal homo-
genates of Ts65Dn and euploid mice. A two-way ANOVA on p-ERK1
levels showed no genotype × treatment interaction [F(1,29) = 0.78,
p = 0.385], but a main effect of genotype [F(1,29) = 7.21, p = 0.012]
and of treatment [F(1,29) = 4.64, p = 0.040]. Post-hoc Fisher LSD test
showed that treated Ts65Dn mice underwent an increase in p-ERK1
levels in comparison with untreated Ts65Dn mice as well as untreated
euploid mice (Fig. 6F). A two-way ANOVA on p-ERK2 levels showed no
genotype × treatment interaction [F(1,29) = 1.73, p = 0.199], a main
effect of genotype [F(1,29) = 8.92, p = 0.006] but no main effect of
treatment. Post-hoc Fisher LSD test showed that treated Ts65Dn mice
underwent an increase in p-ERK2 levels in comparison with untreated
euploid mice (Fig. 6F). A two-way ANOVA on the levels of ERK1
showed no genotype × treatment interaction [F(1,28) = 0.815,
p = 0.374] and no main effect of either treatment or genotype. Post-hoc
Fisher LSD test showed that treated Ts65Dn mice underwent an in-
crease in ERK1 levels in comparison with untreated Ts65Dn mice
(Fig. 6G). A two-way ANOVA on the levels of ERK2 showed no geno-
type × treatment interaction [F(1,30) = 0.065, p = 0.801], no main
effect of genotype, but a main effect of treatment [F(1,30) = 13.76,
p = 0.001]. Post-hoc Fisher LSD test showed that Ts65Dn mice treated
with 7,8-DHF underwent an increase in ERK2 levels in comparison with
their untreated counterparts and untreated euploid mice (Fig. 6G). An
increase in ERK2 levels also took place in treated euploid mice in
comparison with their untreated counterparts (Fig. 6G). There is evi-
dence that ERK2 is approximately four time more abundant than ERK1
in various brain regions and that alteration of the stoichiometry of the
two isoform of ERK may have adverse effects (Lefloch et al., 2008).
Therefore, we examined the relative abundance of ERK1/ERK2 and p-
ERK1/ERK2 in treated and untreated mice. We found that in the hip-
pocampal region of untreated euploid and Ts65Dn mice the ratio be-
tween ERK2 and ERK1 was approximately 3:1 and the ratio between p-
ERK2 and p-ERK1 was approximately 2:1 (Supplementary Table 8).
Although in absolute terms treatment increased the levels of ERK1/2
and p-ERK1/2 in Ts65Dn mice (Fig. 6F,G), it did not affect their stoi-
chiometry (Supplementary Table 8).
3.8. Effect of 7,8-DHF on hippocampus-dependent learning and memory
At the age of P45 (an age approximately corresponding to adoles-
cence), mice can be behaviorally tested with tasks that explore hippo-
campus-dependent learning and memory (Stagni et al., 2016). In order
to establish whether the neuroanatomical effects of 7,8-DHF are func-
tionally effective, we treated euploid and Ts65Dn mice from P3 to P45-
50 and examined their behavior with the Morris Water Maze (MWM)
test, a test that is classically used in trisomic mice to assess the effects of
genotype and/or treatment on memory.
The learning phase of the test lasted 5 days and on day six mice
were subjected to the probe test in order to evaluate spatial memory.
For the learning phase, the following variables were evaluated: escape
latency, time in periphery, percentage of time in periphery, path length,
proximity, and swimming speed. We carried out a three-way mixed
ANOVA for all variables followed by post-hoc Fisher LSD test. Results of
ANOVA are reported hereafter and results of the post-hoc test are
summarized in Table 2.
A three-way mixed ANOVA on escape latency, with genotype and
treatment as grouping factors and day as a repeated measure revealed
no effect of genotype × treatment × day [F(4,228) = 1.52,
p = 0.196]. We found a genotype × day interaction [F(4,228) = 3.10,
p = 0.016], a treatment × day interaction [F(4,228) = 2.77,
p = 0.028], no genotype × treatment interaction [F(1,57) = 0.03,
p = 0.874], a main effect of genotype [F(1,57) = 42.58, p≤ 0.001], a
main effect of treatment [F(1,57) = 10.14, p = 0.002], and a main
effect of day [F(4,228) = 21.75, p≤ 0.001]. While euploid mice ex-
hibited a fast learning improvement with time, untreated Ts65Dn mice
exhibited a very scarce learning improvement and the latency to reach
the platform did not decrease throughout the test (Fig. 7A, Table 2). In
contrast, Ts65Dn mice treated with 7,8-DHF showed a learning im-
provement and, save for day 3, their performance was not statistically
different from that of untreated euploid mice (Fig. 7A, Table 2). In
euploid mice treated with 7,8-DHF the latency was reduced in com-
parison with that of untreated euploid mice (Fig. 7A), although the
difference was statistically significant on day 2 only (Table 2).
A three-way mixed ANOVA on the time spent at the periphery zone
(thigmotaxis), with genotype and treatment as grouping factors and day
as a repeated measure revealed an effect of genotype × -
treatment × day [F(4,228) = 2.88, p = 0.023]. We found no genoty-
pe × day interaction [F(4,228) = 0.99, p = 0.412], a treatment × day
interaction [F(4,228) = 3.31, p = 0.012], no genotype × treatment
interaction [F(1,57) = 0.001, p = 0.992], a main effect of genotype [F
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(1,57) = 19.63, p≤ 0.001], a main effect of treatment [F(1,57)
= 8.07, p = 0.006], and a main effect of day [F(4,228) = 27.72,
p≤ 0.001]. A post-hoc Fisher LSD test showed that while untreated
Ts65Dn mice spent more time at the periphery than untreated euploid
mice, Ts65Dn mice treated with 7,8-DHF spent a similar time as euploid
mice (Fig. 7B, Table 2), suggesting an improvement in searching
strategy. A reduction in thigmotaxis was also shown by euploid mice
treated with 7,8-DHF.
A three-way mixed ANOVA on the percentage of time spent at the
periphery, with genotype and treatment as grouping factors and day as
a repeated measure revealed an effect of genotype × treatment × day
[F(4,228) = 3.01, p = 0.019]. We found a genotype × day interaction
[F(4,228) = 2.47, p = 0.045], a treatment × day interaction [F
(4,228) = 7.76, p≤ 0.001], no genotype × treatment interaction [F
(1,57) = 1.48, p = 0.229], a main effect of genotype [F(1,57) = 11.71,
p = 0.001], a main effect of treatment [F(1,57) = 8.04, p = 0.006],
and a main effect of day [F(4,228) = 23.88, p≤ 0.001]. Post-hoc Fisher
LSD test showed that the time spent at the periphery by untreated
Ts65Dn mice, expressed as percentage of the total latency, was similar
to that of untreated euploid mice (Fig. 7C, Table 2). This means that the
proportion of time spent at the periphery and outside the periphery was
similar in euploid and Ts65Dn mice. Since in Ts65Dn mice the total
latency to reach the platform was longer than in euploid mice, this
means that Ts65Dn mice spent more time at the periphery as well as
swimming outside the periphery, which implies that their longer escape
latency can be attributed to both higher thigmotaxis levels and poorer
spatial learning. In treated Ts65Dn mice the percentage of time in
thigmotaxis underwent a reduction and on day 5 it was significantly
different in comparison with their untreated counterparts (Fig. 7C,
Table 2), suggesting an improvement in spatial learning.
A three-way mixed ANOVA on path length, with genotype and
treatment as grouping factors and day as a repeated measure revealed
no effect of genotype × treatment × day [F(4,228) = 2.09,
p = 0.082]. We found a genotype × day interaction [F(4,228) = 7.80,
p≤ 0.001], no treatment × day interaction [F(4,228) = 0.54
p = 0.707], no genotype × treatment interaction [F(1,57) = 0.05,
Fig. 6. Effects of neonatal treatment with 7,8-DHF on the
BDNF-TrkB receptor system in the hippocampal formation
of P15 Ts65Dn and euploid mice. Western blot analysis of
the BDNF-TrkB receptor system in the hippocampal for-
mation of P15 Ts65Dn and euploid mice that received ei-
ther vehicle or 7,8-DHF in the postnatal period P3-P15. A:
representative Western blots showing immunoreactivity for
the phosphorylated TrkB receptor (p-TrkB-FL), the full
length TrkB receptor (TrkB-FL), the truncated TrkB re-
ceptor (TrkB-T1), and the housekeeping gene GAPDH. B:
Levels of BDNF (untreated euploid mice: n = 20; untreated
Ts65Dn mice: n = 21; treated euploid mice: n = 5; treated
Ts65Dn mice: n = 6) and representative Western blots
showing immunoreactivity for BDNF and the housekeeping
gene GAPDH. C: Levels of TrkB-FL (untreated euploid mice:
n = 19; untreated Ts65Dn mice: n = 19; treated euploid
mice: n = 5; treated Ts65Dn mice: n = 6). D: Levels of p-
TrkB-FL (untreated euploid mice: n = 15; untreated
Ts65Dn mice: n = 16; treated euploid mice: n = 5; treated
Ts65Dn mice: n = 6). E: levels of TrkB-T1 (untreated eu-
ploid mice: n = 19; untreated Ts65Dn mice: n = 21;
treated euploid mice: n = 5; treated Ts65Dn mice: n = 6).
F–H: Western blot analysis of p-ERK1/p-ERK2 (untreated
euploid mice: n = 10; untreated Ts65Dn mice: n = 12;
treated euploid mice: n = 5; treated Ts65Dn mice: n = 6)
(F) and total ERK1/ERK2 levels (untreated euploid mice:
n = 11; untreated Ts65Dn mice: n = 11; treated euploid
mice: n = 5; treated Ts65Dn mice: n = 6) (G) and re-
presentative Western blots (H) showing immunoreactivity
for p-ERK1, p-ERK2, ERK1, ERK2 and for the housekeeping
protein α-Tubulin. Data in (B, C, E) were normalized to
GAPDH; data in (G) were normalized to α-Tubulin; data in
(D) were normalized to TrkB-FL, and data in (F) were
normalized to total ERK1 and total ERK2, respectively.
Protein levels (mean ± SE) are expressed as fold differ-
ence in comparison with untreated euploid mice.
*p≤ 0.05; **p≤ 0.01; ***p≤ 0.001 (Fisher LSD test after
two-way ANOVA). Black asterisks in the gray bar indicate a
difference between untreated Ts65Dn mice and treated
euploid mice. White asterisks in the black bar indicate a
difference between treated Ts65Dn mice and treated eu-
ploid mice. Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone;
Eu, euploid; Veh, vehicle.
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p = 0.819], no main effect of genotype, no main effect of treatment but
a main effect of day [F(4,228) = 43.74, p≤ 0.001]. In all groups, the
path length decreased from day 1 to day 5 (Fig. 7D). In untreated
Ts65Dn mice, the reduction was smaller than in untreated euploid mice
and on day 5 their path length was significantly greater in comparison
with untreated euploid mice (Fig. 7D, Table 2). In contrast, on day 5 the
path length of treated Ts65Dn mice was shorter in comparison with
their untreated counterparts and equal to that of treated and untreated
euploid mice, suggesting an improvement in searching strategy.
A three-way mixed ANOVA on proximity to the former platform
position (Gallagher's test; proximity), with genotype and treatment as
grouping factors and day as a repeated measure revealed an effect of
genotype × treatment × day [F(4,228) = 2.59, p = 0.038]. We found
a genotype × day interaction [F(4,228) = 3.93, p = 0.004], a treat-
ment × day interaction [F(4,228) = 4.79, p≤ 0.001], no genoty-
pe × treatment interaction [F(1,57) = 1.12, p = 0.295], a main effect
of genotype [F(1,57) = 9.66, p = 0.003], a main effect of treatment [F
(1,57) = 12.91, p = 0.001], and a main effect of day [F(4,228)
= 13.39, p≤ 0.001]. Fig. 7E shows that while in untreated euploid
mice the distance from the platform position decreased from day 1 to
day 5, untreated Ts65Dn mice underwent no improvement. In contrast,
treated Ts65Dn mice underwent an improvement and on day 5 their
distance from the platform was significantly reduced in comparison
with their untreated counterparts and similar to that of untreated and
treated euploid mice (Fig. 7E, Table 2).
A three-way mixed ANOVA on swimming speed, with genotype and
treatment as grouping factors and day as a repeated measure revealed
an effect of genotype × treatment × day [F(4,228) = 3.20,
p = 0.014]. We found no genotype × day interaction [F(4,228)
= 0.71, p = 0.584], no treatment × day interaction [F(4,228) = 1.98,
p = 0.098], no genotype × treatment interaction [F(1,57) = 0.09,
p = 0.760], a main effect of genotype [F(1,57) = 5.27, p = 0.025], no
main effect of treatment, but a main effect of day [F(4,228) = 20.05,
p≤ 0.001]. A post-hoc Fisher LSD test showed that in untreated Ts65Dn
mice the swimming speed was similar to that of untreated euploid mice
and treated euploid and Ts65Dn mice throughout the learning phase
(Fig. 7F, Table 2), suggesting that their longer escape latency was not
due to a speed reduction. Treated Ts65Dn mice had a reduced speed in
comparison with untreated euploid mice on days 1, 2, and 3 but similar
to that of euploid mice on days 4 and 5, suggesting that their reduced
escape latency was not due to an improvement in swimming speed.
Treated euploid mice had a reduced speed in comparison with un-
treated euploid mice on day 1, but a similar speed on days 2–5 (Fig. 7F,
Table 2).
In the probe test, we considered the following parameters as an
index of spatial memory: i) latency to enter the former platform zone
(latency), ii) frequency of entrances in the former quadrant (frequency),
iii) proximity to the former platform position (Gallagher's test; proxi-
mity), iv) percentage of time spent at the periphery (thigmotaxis); v)
swimming speed; vi) percentage of time spent in each quadrant. A two-
way ANOVA on the latency showed no genotype × treatment interac-
tion [F(1,57) = 0.87, p = 0.356], but a main effect of genotype [F
(1,57) = 10.24, p = 0.002] and a main effect of treatment [F(1,57)
= 4.60, p = 0.036]. Post-hoc Fisher LSD test showed that untreated
Ts65Dn mice exhibited a larger latency than euploid mice and that
treatment caused a notable reduction in their latency that became si-
milar to that of untreated euploid mice (Fig. 8A). A two-way ANOVA on
the frequency showed no genotype × treatment interaction [F(1,57)
= 0.001, p = 0.992], but a main effect of genotype [F(1,57) = 10.06,
p = 0.002] and a main effect of treatment [F(1,57) = 7.46,
p = 0.008]. Post-hoc Fisher LSD test showed that untreated Ts65Dn
mice exhibited a reduced frequency of entrances than euploid mice. In
treated Ts65Dn mice there was a notable increase in the frequency that
became similar to that of untreated euploid mice (Fig. 8B). A large
increase in the frequency of entrances took place in treated euploid
mice (Fig. 8B). This effect is in line with the reduction in the percentageTa
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of time they spent at the periphery (Fig. 8F). A two-way ANOVA on the
proximity showed no genotype × treatment interaction [F(1,57)
= 1.60, p = 0.211], but a main effect of genotype [F(1,57) = 4.81,
p = 0.032] and a main effect of treatment [F(1,57) = 7.05,
p = 0.010]. Post-hoc Fisher LSD test showed that untreated Ts65Dn
mice swam at a larger distance from the former platform zone in
comparison with untreated euploid mice (Fig. 8C). Treated Ts65Dn
mice swam closer to the former platform zone and their performance
became similar to that of untreated euploid mice (Fig. 8C).
A two-way ANOVA on the percentage of time spent at the periphery
showed no genotype × treatment interaction [F(1,57) = 0.62,
p = 0.436], no main effect of genotype but a main effect of treatment
[F(1,57) = 12.03, p = 0.001]. Post-hoc Fisher LSD test showed that in
untreated Ts65Dn mice the percentage of time spent at the periphery
was similar to that of untreated euploid mice (Fig. 8D). The finding that
Ts65Dn mice spent the same proportion of time in and outside the
periphery as euploid mice suggests that their longer escape latency
(Fig. 8A) can be attributed to poorer spatial memory for the former
platform location. In treated Ts65Dn mice the percentage of time spent
in the periphery was reduced in comparison with their untreated
counterparts (Fig. 8D), suggesting an improvement in searching
strategy. A reduction in the percentage of time at the periphery was also
exhibited by treated vs. untreated euploid mice (Fig. 8D).
A two-way ANOVA on the swimming speed showed no genoty-
pe × treatment interaction [F(1,57) = 0.44, p = 0.511], no main
effect of genotype and no main effect of treatment and post-hoc Fisher
LSD test showed no differences between groups (Fig. 8E).
A paired samples t-test showed that untreated Ts65Dn mice ex-
hibited no differences in the time spent in the former platform quadrant
in comparison with the other quadrants (Fig. 8F). In contrast, treated
Ts65Dn mice spent significantly more time in the former platform
quadrant in comparison with the NE quadrant [t(14) = 2.49;
p = 0.026] and with the SE quadrant, although the latter difference
was only marginally significant [t(14) = 2.05; p = 0.059]. Untreated
euploid mice spent significantly more time in the former platform
quadrant in comparison with the NE [t(15) = 3.09; p = 0.008] and SE
quadrant [t(15) = 2.16; p = 0.047] quadrants. Likewise, treated eu-
ploid mice spent significantly more time in the former platform quad-
rant in comparison with the NE [t(15) = 3.85; p = 0.002] and SE
quadrant [t(15) = 6.02; p≤ 0.001] quadrants (Fig. 8F).
Taken together, these results are in agreement with a number of
studies showing that Ts65Dn mice are impaired in spatial learning and
memory. In treated Ts65Dn mice, the parameters of the learning phase
tended to ameliorate day by day, although not to a significant level, but
at day 5 the performance of Ts65Dn mice underwent a significant im-
provement in comparison with their untreated counterparts and was
similar to that of untreated euploid mice. Importantly, in the probe test
the behavior of treated Ts65Dn mice was similar to that of untreated
euploid mice suggesting memory restoration.
Fig. 7. Effect of treatment with 7,8-DHF on spatial learning
in Ts65Dn and euploid mice. Mice received either vehicle or
7,8-DHF in the period P3-P45-50 and were behaviorally
tested with the MWM starting from 6 days before reaching
45–50 days of age (untreated euploid mice: n = 16; un-
treated Ts65Dn mice: n = 14; treated euploid mice: n = 16;
treated Ts65Dn mice: n = 15). The curves in (A–F) report
data of euploid mice that received either vehicle (empty
circle) or 7,8-DHF (filled circle) and Ts65Dn mice that re-
ceived either vehicle (empty square) or 7,8-DHF (filled
square). A–E: Learning phase of the MWM evaluated as la-
tency to reach the platform (A), time spent at the periphery
(thigmotaxis) (B), percentage of time spent at the periphery
(C), path length (D), and proximity to the platform zone (E).
F: Swimming speed. B–D: Values represent mean ± SE.
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid;
sec, seconds.
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4. Discussion
This study shows that treatment with a BDNF mimetic restores
hippocampal neurogenesis, dendritic spine density and largely im-
proves behavior. It must be observed that the Ts65Dn mouse is trisomic
for at least 55% of HSA21 orthologous protein-coding genes, but it lacks
the remaining ~45%. Moreover, it bears 50 protein-coding genes that
are not orthologs for HSA21 genes, a segment that is an artifact of the
method used in its construction (Duchon et al., 2011; Reinholdt et al.,
2011). Although the Ts65Dn mouse shows genetic limitations, it is still
the most popular choice among DS models because it recapitulates
many aspects of the human condition, including cytoarchitectural ab-
normalities in many brain regions and deficits in learning and memory
(see (Bartesaghi et al., 2011, Rueda et al., 2012, Gardiner, 2015)).
Moreover, the Ts65Dn mouse is the only DS model that has been used in
preclinical evaluation of drugs for learning and memory (see (Gardiner,
2015)). Unfortunately, a perfect mouse model of DS does not presently
exist although intense efforts are currently underway (Antonarakis,
2017). We hope that current results in the Ts65Dn mouse model may
prompt further studies in other models of DS.
4.1. Treatment with the BDNF mimetic 7,8-DHF positively impacts the
major defects of hippocampal development in Ts65Dn mice
At variance with adult Ts65Dn mice (Bimonte-Nelson et al., 2003;
Fukuda et al., 2010; Begenisic et al., 2015), we found here no reduction
in BDNF protein levels in the hippocampus of P15 Ts65Dn mice, sug-
gesting that BDNF expression may be developmentally regulated. Al-
though neonate Ts65Dn mice exhibited similar BDNF levels as those of
euploid mice, treatment with the BDNF mimetic 7,8-DHF resulted in the
recovery of the major trisomy-linked developmental defects, i.e. neu-
rogenesis reduction and dendritic pathology, which is in line with the
key role played by BDNF in brain development.
In particular, we found that treatment with 7,8-DHF increased the
Fig. 8. Effect of treatment with 7,8-DHF on spatial memory
in Ts65Dn and euploid mice. Spatial memory was assessed
in the probe test after spatial learning (same mice as in
Fig. 7). In the probe test, memory was assessed as latency to
reach the former platform zone (A), number of crossings
(frequency) over the former platform quadrant (B), proxi-
mity to the former platform zone (C), percentage of time
spent at the periphery (D), percentage of time spent in
quadrants (F). E: Swimming speed during the probe test.
Values represent mean ± SE. (*) p≤ 0.06; *p≤ 0.05;
**p≤ 0.01; ***p≤ 0.001 (Fisher LSD test after ANOVA).
Black asterisks in the gray bar indicate a difference between
untreated Ts65Dn mice and treated euploid mice; white
asterisks in the black bar indicate a difference between
treated Ts65Dn mice and treated euploid mice. The symbol
§ in (F) indicates a difference between each individual
quadrant and the former platform quadrant (see key on the
left) for each experimental group. (§) p≤ 0.06; § p≤ 0.05;
§§ p≤ 0.01; §§§ p≤ 0.001 (two-sample paired t-test).
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid;
NE, north-east; NW, north-west; SE, south-east; SW, south-
west; sec, seconds.
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number of dividing cells in the SGZ of Ts65Dn mice. While in untreated
Ts65Dn mice the number of proliferating cells was −30% in compar-
ison with untreated euploid mice, in treated Ts65Dn mice their number
became −13% (see Fig. 3C), indicating that, although 7,8-DHF does
not fully rescue NPC proliferation, it causes a large improvement. It is of
interest to observe that in cultures of NPCs 7,8-DHF failed to increase
cell proliferation (Fig. 1B), although it induced a robust effect on dif-
ferentiation and maturation. This suggests that 7,8-DHF does not di-
rectly induce pro-proliferative signals in NPCs but that its pro-pro-
liferative effects require the presence of other elements of the
neurogenic niche (non-cell autonomous effect). Importantly, although
the number of dividing cells in the SGZ of Ts65Dn mice was not fully
rescued, total granule cell number was fully restored. This result may be
explained by an effect of treatment on the process of phenotype ac-
quisition, with a shift in the relative number of cells destined to become
neurons. This conclusion is in line with the observation that in cultures
of trisomic NPCs treatment largely increased the number of trisomic
cells that differentiated into neurons (Fig. 1C).
We additionally found that 7,8-DHF favors the process of neurite
elongation in trisomic neurons of both the SVZ and SGZ, indicating a
positive impact of treatment on the process of neuron maturation. The
granule neurons of Ts65Dn mice aged 15 days exhibited spine density
reduction, indicating impairment in the process of spinogenesis from
the earliest phases of hippocampal development. As each dendritic
spine receives at least one excitatory input, a reduction in the number
of spines of granule neurons implies a reduction in the number of ex-
citatory terminals and, consequently, reduced complexity of hippo-
campal circuitry. Evaluation of the levels of the presynaptic protein
SYN in Ts65Dn mice showed that the counterpart of the spine density
reduction was a reduction in SYN levels. Treatment with 7,8-DHF fully
restored the reduced number of dendritic spines of Ts65Dn mice as well
as SYN levels, suggesting a positive impact on the overall connectivity
of the DG.
Conflicting results are reported in the literature regarding the pro-
proliferative effect of the BDNF-TrkB system in different species and
cellular systems (Foltran and Diaz, 2016; Vilar and Mira, 2016). Many
studies suggest that BDNF fosters neurogenesis and neuron maturation
but not proliferation of NPCs. Our results suggest that in Ts65Dn mice
activation of the TrkB receptor enhances NPCs proliferation, in addition
to neurogenesis and neuron maturation. Although the effect on pro-
liferation was less prominent than the effect on neurogenesis and
neuron maturation, the outcome was restoration of the defective cel-
lularity in the granule layer of the DG. It is of interest to observe that
some of the neurogenesis-enhancing therapies attempted so far in
mouse models of DS may present caveats for human use due to the risk
of uncontrolled proliferation in peripheral tissues and, thus, a can-
cerogenic effect (Bartesaghi et al., 2011; Gardiner, 2015). The finding
that 7,8-DHF, in spite of its relatively moderate pro-proliferative ac-
tivity, is able to restore the final number of granule neurons may render
this molecule a good candidate for therapy in DS.
4.2. Treatment with 7,8-DHF rescues hippocampus-dependent behavior in
Ts65Dn mice
Hippocampus-dependent learning and memory impairment is a
consistent feature of DS and the Ts65Dn mouse model (Demas et al.,
1996; Carlesimo et al., 1997; Vicari et al., 2000; Belichenko et al., 2007;
Salehi et al., 2009). This defect is attributable to hippocampal hypo-
cellularity, altered neuronal maturation and altered connectivity. The
granule cells of the DG are the first element of the hippocampal trisy-
naptic circuit, a circuit whose function is fundamental for long-term
memory. The dendrites of the granule cells receive their major input
from the entorhinal cortex that represents an interface between the
hippocampal formation and the rest of the brain. Signals from poly-
modal association cortices sent by the entorhinal cortex to the DG are
processed by the trisynaptic circuit and then sent back to the entorhinal
cortex. We found here that in Ts65Dn mice treated with 7,8-DHF there
was an improvement in hippocampus-dependent learning and a rescue
in spatial memory, as assessed in the probe test, indicating that the
effects of treatment on the hippocampal defects that characterize the
trisomic condition translate into a behavioral benefit. It remains to be
established whether after treatment cessation these effects are retained
at further life stages.
4.3. Activation of the TrkB receptor by 7,8-DHF enhances the activity of
TrkB receptor-dependent signaling
In the hippocampus of P15 Ts65Dn mice we found normal levels of
BDNF, TrkB-FL, and TrkB-T1 receptors. Results showed reduced levels
of BDNF and TrkB-FL receptor in Ts65Dn mice after thirteen days of
treatment with 7,8-DHF, suggesting a compensatory reduction of their
transcription and/or an increase in their degradation. There is evidence
that treatment with BDNF or the BDNF mimetic 7,8-DHF elicits TrkB
receptor ubiquitination and degradation (Liu et al., 2016). This me-
chanism may account for the reduction in the protein levels of the TrkB
receptor observed here in treated Ts65Dn mice. The absence of a similar
reduction in treated euploid mice suggests that the mechanisms un-
derlying degradation of the TrkB receptor may be more powerful in the
trisomic brain. It must be noted that, although treatment induced an
overall reduction in TrkB receptor levels, its phosphorylation increased,
indicating that treatment enhances TrkB-dependent signaling.
The cellular effects of the BDNF-TrkB system are mediated by three
major pathways, among which the RAS/MEK/ERK pathway appears to
be involved in key developmental processes such as differentiation and
survival (Arevalo and Wu, 2006). We found that in treated Ts65Dn mice
there was an increase in the levels of p-ERK1 and p-ERK2, which is
consistent with the treatment-induced phosphorylation increase of the
TrkB receptor. ERK activity is required for cell proliferation (Lefloch
et al., 2008), and there is evidence that the BDNF-TrkB signaling-in-
duced increase in spine density of hippocampal pyramidal neurons re-
quires ERK1/2 activation (Alonso et al., 2004). This evidence strongly
suggests that the increased activity of ERK1/2 following treatment with
7,8-DHF may represent a key contributor to the rescue of the key
processes of hippocampal development in Ts65Dn mice.
Although much is now known regarding the role of ERK1/2, the
mechanisms underlying their expression still need to be elucidated
(Busca et al., 2016). We found here that treatment with 7,8-DHF in-
creased both ERK1 and ERK2 levels. A recent study shows that the ratio
between total ERK1 and ERK2 protein levels in different mouse brain
regions is about 1:4, that the same ratio holds for p-ERK1/2 and that
derangement of these ratios has adverse effects on the brain (Lefloch
et al., 2008). Importantly, in Ts65Dn mice, treatment caused an in-
crease in ERK1/2 and p-ERK1/2 but their ratios remained similar to
those of their untreated counterparts. This indicates that treatment
enhances the activity of ERK1/2 without disrupting the important
balance between the two ERK isoforms.
4.4. Treatment with 7,8-DHF has no adverse effects on viability and growth
of Ts65Dn mice
Previous evidence showed that chronic treatment with 7,8-DHF has
no toxic effects (Liu et al., 2016). In agreement with this evidence, we
found no effect of treatment on mice viability. There is evidence that in
rodents treatment with BDNF causes a reduction in food intake and that
activation of muscular TrkB by 7,8-DHF regulates energy metabolism in
muscles (Gray et al., 2006; Chan et al., 2015). Conversely, rodent
models with a reduction in BDNF-TrkB signaling exhibit hyperphagia
and obesity (Gray et al., 2006). We found that a relatively short treat-
ment with 7,8-DHF (13 days: from P3 to P15) as well as a more pro-
longed treatment (42–47 days: from P3 to P45-50) did not cause a body
weight reduction in Ts65Dn mice. In addition, we did not found an
adverse effect of treatment on the brain weight of Ts65Dn mice, but
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rather, a positive effect on brain growth. From these findings it appears
that a chronic treatment with 7,8-DHF has a safe profile on the general
health of Ts65Dn mice.
4.5. Conclusions
7,8-DHF is a molecule that binds to the TrkB receptor and causes its
dimerization and autophosphorylation, thereby mimicking the actions
of BDNF. This binding replicates many actions of BDNF such as those on
neurogenesis, neuron survival, learning and memory, and synaptogen-
esis. In view of these effects the use of 7,8-DHF in models of various
brain disorders results in therapeutic efficacy (Liu et al., 2016). Our
study provides novel evidence that treatment with 7,8-DHF during the
neonatal period restores the major trisomy-linked neurodevelopmental
defects in the hippocampus of a mouse model of DS.
Neurogenesis in the hippocampal formation, one of the most im-
portant brain regions involved in pattern separation/completion and
memory formation (Rolls, 2016), is severely disrupted in fetuses with
DS (Contestabile et al., 2007; Guidi et al., 2008). Neurogenesis im-
pairment is likely to account for hippocampal hypotrophy and for im-
pairment of hippocampus-dependent memory functions in children
with DS (Vicari et al., 2000). Reduced BDNF levels have been reported
in the brains of fetuses with DS (Guedj et al., 2009; Toiber et al., 2010).
In view of the crucial role played by this neurotrophin in key devel-
opmental processes (neurogenesis and neuron maturation), it is likely
that impairment of BDNF-TrkB receptor signaling plays a significant
role in the neurodevelopmental alterations that characterize DS.
The current results suggest that therapy with the BDNF mimetic 7,8-
DHF may represent a possible strategy for improving brain develop-
ment and memory in children, and possibly in adults, with DS. In spite
of the intrinsic limitations of mouse models, our work suggests that it is
possible to restore trisomy-linked developmental deficits by pharma-
cologically targeting the TrkB receptor with a naturally occurring fla-
vonoid. As pointed out in the Introduction, the problem of pharmaco-
logical interventions is that they are, in most cases, Janus-faced. The
positive effects of many of the drugs used so far in DS models are the
“good face” of Janus but the “bad face” deals with the far-from-irrele-
vant issue of safety. Flavonoids are compounds naturally present in
vegetables and fruits (Rendeiro et al., 2015) and exert beneficial effects
on the brain in health and disease (Spencer, 2008; Williams and
Spencer, 2012). Considering that treatment with 7,8-DHF has no toxic
effects in wild type mice (Liu et al., 2013) and in Ts65Dn mice (current
study), our results suggest that early treatment with 7,8-DHF may re-
present a therapeutic strategy alternative to other drugs and with a
good translational potential for improving brain development in DS.
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